Ibuprofen

證據等級: L5

預測適應症: 7 個

Ibuprofen: From Unrecorded Original Indication to Acromesomelic Dysplasia, Hunter-Thompson Type

One-Sentence Summary

Ibuprofen's original indication and mechanism of action could not be retrieved from the available regulatory sources for this candidate. The TxGNN model's top prediction is Acromesomelic Dysplasia, Hunter-Thompson Type, a rare GDF5-related skeletal dysplasia, but no clinical trials and no literature currently support this direction, and the drug is not marketed in Finland.

Quick Overview

Item	Content
Original Indication	Not recorded in the available regulatory data
Predicted New Indication	Acromesomelic Dysplasia, Hunter-Thompson Type
TxGNN Prediction Score	99.74%
Evidence Level	L5
Finland Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for Ibuprofen in this evidence pack. Based on general pharmacological knowledge, Ibuprofen is a non-selective COX-1/COX-2 inhibitor with analgesic and anti-inflammatory activity, but this was not confirmed through the DrugBank query underlying this candidate.

Acromesomelic Dysplasia, Hunter-Thompson Type is a rare skeletal dysplasia caused by GDF5 mutations affecting endochondral ossification — a pathway unrelated to prostaglandin synthesis or COX inhibition. The evidence pack's own mechanistic assessment states there is no known mechanistic link between Ibuprofen and the GDF5/BMP signaling pathway, and suggests the high TxGNN score more likely reflects a learned association with joint-symptom comorbidity (e.g., osteoarthritis-type pain management common to skeletal dysplasias) rather than a disease-modifying mechanism.

The remaining six predicted indications (brachyolmia-amelogenesis imperfecta syndrome, myosclerosis, brachyolmia, brachydactyly-syndactyly syndrome, pseudoachondroplasia, and colobomatous microphthalmia-rhizomelic dysplasia syndrome) show the same pattern: TxGNN scores above 99%, but each rationale explicitly notes an absent or purely symptomatic (not disease-modifying) mechanistic basis. This is consistent with the model surfacing a shared "rare skeletal disorder + analgesic comorbidity" signal rather than a genuine repurposing opportunity.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Finland Market Information

Ibuprofen has no active marketing authorizations recorded for this candidate (0 authorizations; market status: not marketed).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The top prediction has no clinical trial or literature support, no confirmed mechanistic link, and the underlying regulatory/safety data (original indication, MOA, TFDA warnings, DDI) are all missing — this candidate does not meet even a minimal evidentiary bar to proceed.

To proceed, the following is needed:

TFDA/EMA package insert (warnings, contraindications, DDI) to clear the blocking safety data gap
Confirmed mechanism of action from DrugBank or primary literature
Independent biological plausibility review of the GDF5/BMP pathway relative to COX inhibition, given the model's own rationale casts doubt on a causal mechanism
Re-screening for lower-ranked but mechanistically stronger candidates, since all seven predictions in this pack score similarly (L5, Hold) with no differentiating evidence
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.